

Luigi Tavazzi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9311439/publications.pdf>

Version: 2024-02-01

266
papers

50,209
citations

3334

91
h-index

1461

220
g-index

276
all docs

276
docs citations

276
times ranked

35478
citing authors

#	ARTICLE	IF	CITATIONS
1	The Effect of Cardiac Resynchronization on Morbidity and Mortality in Heart Failure. <i>New England Journal of Medicine</i> , 2005, 352, 1539-1549.	27.0	5,656
2	Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. <i>European Heart Journal</i> , 2013, 34, 2636-2648.	2.2	2,436
3	Classification of the cardiomyopathies: a position statement from the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. <i>European Heart Journal</i> , 2007, 29, 270-276.	2.2	2,280
4	Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. <i>Lancet</i> , The, 2010, 376, 875-885.	13.7	2,119
5	Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. <i>Lancet</i> , The, 2010, 375, 735-742.	13.7	2,064
6	Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005). <i>European Heart Journal</i> , 2005, 26, 1115-1140.	2.2	1,986
7	ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008. <i>European Journal of Heart Failure</i> , 2008, 10, 933-989.	7.1	1,893
8	Results of the Predictors of Response to CRT (PROSPECT) Trial. <i>Circulation</i> , 2008, 117, 2608-2616.	1.6	1,878
9	Early Protection Against Sudden Death by n-3 Polyunsaturated Fatty Acids After Myocardial Infarction. <i>Circulation</i> , 2002, 105, 1897-1903.	1.6	1,213
10	Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. <i>Lancet</i> , The, 2008, 372, 1223-1230.	13.7	1,178
11	EuroHeart Failure Survey II (EHFS II): a survey on hospitalized acute heart failure patients: description of population. <i>European Heart Journal</i> , 2006, 27, 2725-2736.	2.2	1,063
12	Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. <i>Lancet</i> , The, 2008, 372, 1231-1239.	13.7	954
13	Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiency. <i>European Heart Journal</i> , 2015, 36, 657-668.	2.2	902
14	Resting Heart Rate in Cardiovascular Disease. <i>Journal of the American College of Cardiology</i> , 2007, 50, 823-830.	2.8	867
15	Current state of knowledge on aetiology, diagnosis, management, and therapy of peripartum cardiomyopathy: a position statement from the Heart Failure Association of the European Society of Cardiology Working Group on peripartum cardiomyopathy. <i>European Journal of Heart Failure</i> , 2010, 12, 767-778.	7.1	787
16	Heart rate as a risk factor in chronic heart failure (SHIFT): the association between heart rate and outcomes in a randomised placebo-controlled trial. <i>Lancet</i> , The, 2010, 376, 886-894.	13.7	769
17	European Society of Cardiology: Cardiovascular Disease Statistics 2019. <i>European Heart Journal</i> , 2020, 41, 12-85.	2.2	690
18	Left bundle-branch block is associated with increased 1-year sudden and total mortality rate in 5517 outpatients with congestive heart failure: A report from the Italian network on congestive heart failure. <i>American Heart Journal</i> , 2002, 143, 398-405.	2.7	681

#	ARTICLE	IF	CITATIONS
19	EUR<i>Observational</i> Research Programme: regional differences and 1â€year followâ€up results of the Heart Failure Pilot Survey (ESCâ€HF Pilot). <i>European Journal of Heart Failure</i> , 2013, 15, 808-817.	7.1	645
20	HMG-coenzyme A reductase inhibition, type 2 diabetes, and bodyweight: evidence from genetic analysis and randomised trials. <i>Lancet, The</i> , 2015, 385, 351-361.	13.7	562
21	Are hospitalized or ambulatory patients with heart failure treated in accordance with European Society of Cardiology guidelines? Evidence from 12 440 patients of the ESC Heart Failure Longâ€Term Registry. <i>European Journal of Heart Failure</i> , 2013, 15, 1173-1184.	7.1	533
22	Associations of Omega-3 Fatty Acid Supplement Use With Cardiovascular Disease Risks. <i>JAMA Cardiology</i> , 2018, 3, 225.	6.1	526
23	Efficacy and safety of statin therapy in older people: a meta-analysis of individual participant data from 28 randomised controlled trials. <i>Lancet, The</i> , 2019, 393, 407-415.	13.7	512
24	Genetic counselling and testing in cardiomyopathies: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. <i>European Heart Journal</i> , 2010, 31, 2715-2726.	2.2	408
25	Outcome of pregnancy in patients with structural or ischaemic heart disease: results of a registry of the European Society of Cardiology. <i>European Heart Journal</i> , 2013, 34, 657-665.	2.2	378
26	Cardiovascular event rates and mortality according to achieved systolic and diastolic blood pressure in patients with stable coronary artery disease: an international cohort study. <i>Lancet, The</i> , 2016, 388, 2142-2152.	13.7	357
27	Coâ€morbidity in patients with heart failure: an analysis of the European Heart Failure Pilot Survey. <i>European Journal of Heart Failure</i> , 2014, 16, 103-111.	7.1	355
28	Declining Risk of Sudden Death in Heart Failure. <i>New England Journal of Medicine</i> , 2017, 377, 41-51.	27.0	355
29	Adherence to guidelines is a predictor of outcome in chronic heart failure: the MAHLER survey. <i>European Heart Journal</i> , 2005, 26, 1653-1659.	2.2	354
30	Diagnostic work-up in cardiomyopathies: bridging the gap between clinical phenotypes and final diagnosis. A position statement from the ESC Working Group on Myocardial and Pericardial Diseases. <i>European Heart Journal</i> , 2013, 34, 1448-1458.	2.2	346
31	EUR<i>Observational</i> Research Programme: The Heart Failure Pilot Survey (ESCâ€HF Pilot). <i>European Journal of Heart Failure</i> , 2010, 12, 1076-1084.	7.1	340
32	Long-Term Outcome and Risk Stratification in Dilated Cardiomyopathies. <i>Journal of the American College of Cardiology</i> , 2008, 52, 1250-1260.	2.8	335
33	A genome-wide association study identifies two loci associated with heart failure due to dilated cardiomyopathy. <i>European Heart Journal</i> , 2011, 32, 1065-1076.	2.2	292
34	A prospective survey in European Society of Cardiology member countries of atrial fibrillation management: baseline results of EURObservational Research Programme Atrial Fibrillation (EORP-AF) Pilot General Registry. <i>Europace</i> , 2014, 16, 308-319.	1.7	280
35	The importance of patient-reported outcomes: a call for their comprehensive integration in cardiovascular clinical trials. <i>European Heart Journal</i> , 2014, 35, 2001-2009.	2.2	274
36	Effects of selective heart rate reduction with ivabradine on left ventricular remodelling and function: results from the SHIFT echocardiography substudy. <i>European Heart Journal</i> , 2011, 32, 2507-2515.	2.2	264

#	ARTICLE	IF	CITATIONS
37	Clinical Impact of OCT Findings During PCI. JACC: Cardiovascular Imaging, 2015, 8, 1297-1305.	5.3	255
38	Sensitivity and positive predictive value of implantable intrathoracic impedance monitoring as a predictor of heart failure hospitalizations: the SENSE-HF trial. European Heart Journal, 2011, 32, 2266-2273.	2.2	249
39	Contemporary management of octogenarians hospitalized for heart failure in Europe: Euro Heart Failure Survey II. European Heart Journal, 2008, 30, 478-486.	2.2	247
40	Asymptomatic Atrial Fibrillation: Clinical Correlates, Management, and Outcomes in the EORP-AF Pilot General Registry. American Journal of Medicine, 2015, 128, 509-518.e2.	1.5	242
41	Effects on Outcomes of Heart Rate Reduction by Ivabradine in Patients With Congestive Heart Failure: Is There an Influence of Beta-Blocker Dose?. Journal of the American College of Cardiology, 2012, 59, 1938-1945.	2.8	233
42	Nationwide survey on acute heart failure in cardiology ward services in Italy. European Heart Journal, 2005, 27, 1207-1215.	2.2	215
43	Rationale and design of the GISSI heart failure trial: a large trial to assess the effects of n-3 polyunsaturated fatty acids and rosuvastatin in symptomatic congestive heart failure. European Journal of Heart Failure, 2004, 6, 635-641.	7.1	214
44	Serial Measurement of Cardiac Troponin T Using a Highly Sensitive Assay in Patients With Chronic Heart Failure. Circulation, 2012, 125, 280-288.	1.6	209
45	Pregnancy outcomes in women with cardiovascular disease: evolving trends over 10 years in the ESC Registry Of Pregnancy And Cardiac disease (ROPAC). European Heart Journal, 2019, 40, 3848-3855.	2.2	209
46	Prognosis and treatment of atrial fibrillation patients by European cardiologists: One Year Follow-up of the EURObservational Research Programme-Atrial Fibrillation General Registry Pilot Phase (EORP-AF) Tj ETQq0 0 0.2gBT /Ovzok 10 T	2.2	204
47	The MOGE(S) Classification for a Phenotypeâ€“Genotype Nomenclature of Cardiomyopathy. Journal of the American College of Cardiology, 2013, 62, 2046-2072.	2.8	203
48	Fish Oil and Postoperative Atrial Fibrillation. JAMA - Journal of the American Medical Association, 2012, 308, 2001.	7.4	201
49	Heart rate at baseline influences the effect of ivabradine on cardiovascular outcomes in chronic heart failure: analysis from the SHIFT study. Clinical Research in Cardiology, 2013, 102, 11-22.	3.3	199
50	Physicians' adherence to guidelineâ€“recommended medications in heart failure with reduced ejection fraction: data from the <sc>QUALIFY</sc> global survey. European Journal of Heart Failure, 2016, 18, 514-522.	7.1	193
51	Physicians' guideline adherence is associated with better prognosis in outpatients with heart failure with reduced ejection fraction: the <sc>QUALIFY</sc> international registry. European Journal of Heart Failure, 2017, 19, 1414-1423.	7.1	183
52	Clinical outcome endpoints in heart failure trials: a European Society of Cardiology Heart Failure Association consensus document. European Journal of Heart Failure, 2013, 15, 1082-1094.	7.1	182
53	The Atrial Fibrillation Ablation Pilot Study: an European Survey on Methodology and results of catheter ablation for atrial fibrillation conducted by the European Heart Rhythm Association. European Heart Journal, 2014, 35, 1466-1478.	2.2	180
54	Heart rate reduction with ivabradine and health related quality of life in patients with chronic heart failure: results from the SHIFT study. European Heart Journal, 2011, 32, 2395-2404.	2.2	175

#	ARTICLE	IF	CITATIONS
55	Clinical outcome of renal tubular damage in chronic heart failure. European Heart Journal, 2011, 32, 2705-2712.	2.2	174
56	Multicenter Prospective Observational Study on Acute and Chronic Heart Failure. Circulation: Heart Failure, 2013, 6, 473-481.	3.9	170
57	Wolff-Parkinson-White Syndrome in the Era of Catheter Ablation. Circulation, 2014, 130, 811-819.	1.6	169
58	The 2011-12 pilot European Sentinel Registry of Transcatheter Aortic Valve Implantation: in-hospital results in 4,571 patients. EuroIntervention, 2013, 8, 1362-1371.	3.2	168
59	Sex-related differences in presentation, treatment, and outcome of patients with atrial fibrillation in Europe: a report from the Euro Observational Research Programme Pilot survey on Atrial Fibrillation. Europace, 2015, 17, 24-31.	1.7	164
60	Clinical characteristics of patients from the worldwide registry on peripartum cardiomyopathy (<sc>PPCM</sc>). European Journal of Heart Failure, 2017, 19, 1131-1141.	7.1	163
61	Current management of patients with severe acute peripartum cardiomyopathy: practical guidance from the Heart Failure Association of the European Society of Cardiology Study Group on peripartum cardiomyopathy. European Journal of Heart Failure, 2016, 18, 1096-1105.	7.1	160
62	The MOGE(S) Classification of Cardiomyopathy for Clinicians. Journal of the American College of Cardiology, 2014, 64, 304-318.	2.8	158
63	Prognostic Value of High-Sensitivity Troponin T in Chronic Heart Failure. Circulation, 2018, 137, 286-297.	1.6	157
64	Triage strategy for urgent management of cardiac tamponade: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. European Heart Journal, 2014, 35, 2279-2284.	2.2	154
65	Desmin accumulation restrictive cardiomyopathy and atrioventricular block associated with desmin gene defects. European Journal of Heart Failure, 2006, 8, 477-483.	7.1	153
66	Contemporary management of patients undergoing atrial fibrillation ablation: in-hospital and 1-year follow-up findings from the ESC-EHRA atrial fibrillation ablation long-term registry. European Heart Journal, 2017, 38, ehw564.	2.2	151
67	In-hospital and 1-year mortality associated with diabetes in patients with acute heart failure: results from the ESC-EHRA Heart Failure Long-Term Registry. European Journal of Heart Failure, 2017, 19, 54-65.	7.1	150
68	Metabolic Syndrome and Risk of Cardiovascular Events After Myocardial Infarction. Journal of the American College of Cardiology, 2005, 46, 277-283.	2.8	147
69	The clinical characteristics and investigations planned in patients with stable angina presenting to cardiologists in Europe: from the Euro Heart Survey of Stable Angina. European Heart Journal, 2005, 26, 996-1010.	2.2	144
70	Multipoint left ventricular pacing improves acute hemodynamic response assessed with pressure-volume loops in cardiac resynchronization therapy patients. Heart Rhythm, 2014, 11, 394-401.	0.7	133
71	The predictive value of stable precursor fragments of vasoactive peptides in patients with chronic heart failure: data from the GISSI-heart failure (GISSI-HF) trial. European Journal of Heart Failure, 2010, 12, 338-347.	7.1	129
72	Improved outcomes with European Society of Cardiology guideline-adherent antithrombotic treatment in high-risk patients with atrial fibrillation: a report from the EORP-AF General Pilot Registry. Europace, 2015, 17, 1777-1786.	1.7	128

#	ARTICLE	IF	CITATIONS
73	Effect of ivabradine on recurrent hospitalization for worsening heart failure in patients with chronic systolic heart failure: the SHIFT Study. <i>European Heart Journal</i> , 2012, 33, 2813-2820.	2.2	126
74	Personalized management of atrial fibrillation: Proceedings from the fourth Atrial Fibrillation competence NETWORK/European Heart Rhythm Association consensus conference. <i>Europace</i> , 2013, 15, 1540-1556.	1.7	125
75	Heart failure with preserved ejection fraction: uncertainties and dilemmas. <i>European Journal of Heart Failure</i> , 2015, 17, 665-671.	7.1	124
76	ESC-EURObservational Research Programme: the Atrial Fibrillation Ablation Pilot Study, conducted by the European Heart Rhythm Association. <i>Europace</i> , 2012, 14, 1094-1103.	1.7	123
77	A roadmap to improve the quality of atrial fibrillation management: proceedings from the fifth Atrial Fibrillation Network/European Heart Rhythm Association consensus conference. <i>Europace</i> , 2016, 18, 37-50.	1.7	121
78	Contemporary stroke prevention strategies in 11â€™096 European patients with atrial fibrillation: a report from the EURObservational Research Programme on Atrial Fibrillation (EORP-AF) Long-Term General Registry. <i>Europace</i> , 2018, 20, 747-757.	1.7	118
79	Current presentation and management of heart failure in cardiology and internal medicine hospital units: a tale of two worldsâ€™ the TEMISTOCLE study. <i>American Heart Journal</i> , 2003, 146, 735.	2.7	115
80	Acute heart failure patient profiles, management and inâ€™hospital outcome: results of the Italian Registry on Heart Failure Outcome. <i>European Journal of Heart Failure</i> , 2012, 14, 1208-1217.	7.1	112
81	Association Between Elevated Blood Glucose and Outcome in Acute Heart Failure. <i>Journal of the American College of Cardiology</i> , 2013, 61, 820-829.	2.8	111
82	Selective Heart Rate Reduction With Ivabradine Unloads the Left Ventricle in Heart Failure Patients. <i>Journal of the American College of Cardiology</i> , 2013, 62, 1977-1985.	2.8	104
83	Loss in body weight is an independent prognostic factor for mortality in chronic heart failure: insights from the <sc>GISSâ€™HF</sc> and Valâ€™HeFT</sc> trials. <i>European Journal of Heart Failure</i> , 2015, 17, 424-433.	7.1	104
84	Association Between Diabetes and 1-Year Adverse Clinical Outcomes in a Multinational Cohort of Ambulatory Patients With Chronic Heart Failure: Results From the ESC-HFA Heart Failure Long-Term Registry. <i>Diabetes Care</i> , 2017, 40, 671-678.	8.6	103
85	Prevalence and Prognostic Value of Elevated Urinary Albumin Excretion in Patients With Chronic Heart Failure. <i>Circulation: Heart Failure</i> , 2010, 3, 65-72.	3.9	101
86	Predictors of Mortality in 6975 Patients With Chronic Heart Failure in the Gruppo Italiano per lo Studio della Streptochinasi nell'Infarto Miocardico-Heart Failure Trial. <i>Circulation: Heart Failure</i> , 2013, 6, 31-39.	3.9	101
87	Clinical presentation, management, and 6-month outcomes in women with peripartum cardiomyopathy: an ESC EORP registry. <i>European Heart Journal</i> , 2020, 41, 3787-3797.	2.2	101
88	<sc>EURObservational</sc> Research Programme: a worldwide registry on peripartum cardiomyopathy (<sc>PPCM</sc>) in conjunction with the Heart Failure Association of the European Society of Cardiology Working Group on <sc>PPCM</sc>. <i>European Journal of Heart Failure</i> , 2014, 16, 583-591.	7.1	99
89	Favourable effects of heart rate reduction with intravenous administration of ivabradine in patients with advanced heart failureâ€™†. <i>European Journal of Heart Failure</i> , 2008, 10, 550-555.	7.1	98
90	In-hospital and 1-year outcomes of acute heart failure patients according to presentation (de novo vs.) Tj ETQq0 0 0 rgBT /Overlock 10 T <i>Cardiology</i> , 2014, 173, 163-169.	1.7	98

#	ARTICLE	IF	CITATIONS
91	Improving cardiac resynchronization therapy response with multipoint left ventricular pacing: Twelve-month follow-up study. <i>Heart Rhythm</i> , 2015, 12, 1250-1258.	0.7	98
92	Risk of Malignant Arrhythmias in Initially Symptomatic Patients With Wolff-Parkinson-White Syndrome. <i>Circulation</i> , 2012, 125, 661-668.	1.6	96
93	Incremental benefit of drug therapies for chronic heart failure with reduced ejection fraction: a network meta-analysis. <i>European Journal of Heart Failure</i> , 2018, 20, 1315-1322.	7.1	96
94	Heart rate reduction in cardiovascular disease and therapy. <i>Clinical Research in Cardiology</i> , 2011, 100, 11-19.	3.3	95
95	The Cardiomyopathy Registry of the EURObservational Research Programme of the European Society of Cardiology: baseline data and contemporary management of adult patients with cardiomyopathies. <i>European Heart Journal</i> , 2018, 39, 1784-1793.	2.2	94
96	Performance of Prognostic Risk Scores in Chronic Heart Failure Patients Enrolled in the European Society of Cardiology Heart Failure Long-Term Registry. <i>JACC: Heart Failure</i> , 2018, 6, 452-462.	4.1	94
97	Treatment with insulin is associated with worse outcome in patients with chronic heart failure and diabetes. <i>European Journal of Heart Failure</i> , 2018, 20, 888-895.	7.1	93
98	Risk of Stroke in Chronic Heart Failure Patients Without Atrial Fibrillation. <i>Circulation</i> , 2015, 131, 1486-1494.	1.6	92
99	Pentraxin-3 in chronic heart failure: the CORONA and GISSI-HF trials. <i>European Journal of Heart Failure</i> , 2012, 14, 992-999.	7.1	91
100	Rationale and design of a randomized, double-blind, placebo-controlled outcome trial of ivabradine in chronic heart failure: the Systolic Heart Failure Treatment with the I _f Inhibitor Ivabradine Trial (SHIFT). <i>European Journal of Heart Failure</i> , 2010, 12, 75-81.	7.1	88
101	Tubular Damage and Worsening Renal Function in Chronic Heart Failure. <i>JACC: Heart Failure</i> , 2013, 1, 417-424.	4.1	87
102	Characteristics, treatments and 1-year prognosis of hospitalized and ambulatory heart failure patients with chronic obstructive pulmonary disease in the European Society of Cardiology Heart Failure Long-Term Registry. <i>European Journal of Heart Failure</i> , 2018, 20, 100-110.	7.1	86
103	Physicians' guideline adherence is associated with long-term heart failure mortality in outpatients with heart failure with reduced ejection fraction: the QUALIFY international registry. <i>European Journal of Heart Failure</i> , 2019, 21, 921-929.	7.1	86
104	Effect of ivabradine in patients with left-ventricular systolic dysfunction: a pooled analysis of individual patient data from the BEAUTIFUL and SHIFT trials. <i>European Heart Journal</i> , 2013, 34, 2263-2270.	2.2	85
105	Cardiac medication during pregnancy, data from the ROPAC. <i>International Journal of Cardiology</i> , 2014, 177, 124-128.	1.7	85
106	Effective secondary prevention through cardiac rehabilitation after coronary revascularization and predictors of poor adherence to lifestyle modification and medication. Results of the ICAROS Survey. <i>International Journal of Cardiology</i> , 2013, 167, 1390-1395.	1.7	84
107	Physical Activity Measured With Implanted Devices Predicts Patient Outcome in Chronic Heart Failure. <i>Circulation: Heart Failure</i> , 2014, 7, 279-287.	3.9	79
108	Relation of outcomes to ABC (Atrial Fibrillation Better Care) pathway adherent care in European patients with atrial fibrillation: an analysis from the ESC-EHRA EORP Atrial Fibrillation General Long-Term (AFGen LT) Registry. <i>Europace</i> , 2021, 23, 174-183.	1.7	74

#	ARTICLE	IF	CITATIONS
109	Diagnostic Work-Up and Risk Stratification in X-Linked Dilated Cardiomyopathies Caused by Dystrophin Defects. <i>Journal of the American College of Cardiology</i> , 2011, 58, 925-934.	2.8	73
110	Heart rate: a prognostic factor and therapeutic target in chronic heart failure. The distinct roles of drugs with heart rate-lowering properties. <i>European Journal of Heart Failure</i> , 2014, 16, 76-85.	7.1	70
111	Identification and quantification of macrophage presence in coronary atherosclerotic plaques by optical coherence tomography. <i>European Heart Journal Cardiovascular Imaging</i> , 2015, 16, 807-813.	1.2	69
112	Cryoballoon vs. radiofrequency ablation for atrial fibrillation: a study of outcome and safety based on the ESC-EHRA atrial fibrillation ablation long-term registry and the Swedish catheter ablation registry. <i>Europace</i> , 2019, 21, 581-589.	1.7	69
113	Heart failure in patients with atrial fibrillation in Europe: a report from the <sc>EURObservational</sc> Research Programme Pilot survey on Atrial Fibrillation. <i>European Journal of Heart Failure</i> , 2015, 17, 570-582.	7.1	68
114	Local and general anaesthesia do not influence outcome of transfemoral aortic valve implantation. <i>International Journal of Cardiology</i> , 2014, 177, 448-454.	1.7	65
115	Autonomic markers and cardiovascular and arrhythmic events in heart failure patients: still a place in prognostication? Data from the GISSI-HF trial. <i>European Journal of Heart Failure</i> , 2012, 14, 1410-1419.	7.1	64
116	Efficacy and safety of ivabradine in chronic heart failure across the age spectrum: insights from the SHIFT study. <i>European Journal of Heart Failure</i> , 2013, 15, 1296-1303.	7.1	63
117	Circulating microRNA-132 levels improve risk prediction for heart failure hospitalization in patients with chronic heart failure. <i>European Journal of Heart Failure</i> , 2018, 20, 78-85.	7.1	63
118	“Real-world” management and outcomes of patients with paroxysmal vs. non-paroxysmal atrial fibrillation in Europe: the EURObservational Research Programme “Atrial Fibrillation (EORP-AF) General Pilot Registry. <i>Europace</i> , 2016, 18, 648.1-657.	1.7	61
119	Prognostic value of osteoprotegerin in chronic heart failure: The GISSI-HF trial. <i>American Heart Journal</i> , 2010, 160, 286-293.	2.7	60
120	Plasma n-3 polyunsaturated fatty acids in chronic heart failure in the GISSI-Heart Failure Trial: Relation with fish intake, circulating biomarkers, and mortality. <i>American Heart Journal</i> , 2013, 165, 208-215.e4.	2.7	60
121	Efficacy and safety of ivabradine in patients with chronic systolic heart failure according to blood pressure level in <sc>SHIFT</sc>. <i>European Journal of Heart Failure</i> , 2014, 16, 810-816.	7.1	58
122	Efficacy and safety of ivabradine in patients with chronic systolic heart failure and diabetes: an analysis from the <sc>SHIFT</sc> trial. <i>European Journal of Heart Failure</i> , 2015, 17, 1294-1301.	7.1	58
123	European Cardiomyopathy Pilot Registry: EURObservational Research Programme of the European Society of Cardiology. <i>European Heart Journal</i> , 2016, 37, 164-173.	2.2	56
124	Clinical Impact of Suboptimal Stenting and Residual Intrastent Plaque/Thrombus Protrusion in Patients With Acute Coronary Syndrome. <i>Circulation: Cardiovascular Interventions</i> , 2016, 9, .	3.9	55
125	Diagnostic and Therapeutic Gaps in Patients With Heart Failure and Chronic Obstructive Pulmonary Disease. <i>JACC: Heart Failure</i> , 2019, 7, 823-833.	4.1	55
126	Twenty-four-hour heart rate lowering with ivabradine in chronic heart failure: insights from the <sc>SHIFT</sc> Holter substudy. <i>European Journal of Heart Failure</i> , 2015, 17, 518-526.	7.1	54

#	ARTICLE	IF	CITATIONS
127	Influence of Cardiovascular and Noncardiovascular Co-morbidities on Outcomes and Treatment Effect of Heart Rate Reduction With Ivabradine in Stable Heart Failure (from the SHIFT Trial). American Journal of Cardiology, 2015, 116, 1890-1897.	1.6	54
128	International differences in treatment effect: do they really exist and why? European Heart Journal, 2013, 34, 1846-1852.	2.2	53
129	Glomerular filtration rate in patients with atrial fibrillation and 1-year outcomes. Scientific Reports, 2016, 6, 30271.	3.3	51
130	Prognostic Impact of Diabetes and Prediabetes on Survival Outcomes in Patients With Chronic Heart Failure: A Post-Hoc Analysis of the GISSI-HF (Gruppo Italiano per lo Studio della Sopravvivenza nella) Tj ETQq0 0.07rgBT /Overlock 10	3.0	51
131	Multipoint Left Ventricular Pacing in a Single Coronary Sinus Branch Improves Mid-Term Echocardiographic and Clinical Response to Cardiac Resynchronization Therapy. Journal of Cardiovascular Electrophysiology, 2015, 26, 58-63.	1.7	50
132	Genetic Screening of Anderson-Fabry Disease in Proband Referred From Multispecialty Clinics. Journal of the American College of Cardiology, 2016, 68, 1037-1050.	2.8	50
133	Adverse outcomes in patients with atrial fibrillation and peripheral arterial disease: a report from the EURObservational research programme pilot survey on atrial fibrillation. Europace, 2017, 19, 1439-1448.	1.7	47
134	Association between antithrombotic treatment and outcomes at 1-year follow-up in patients with atrial fibrillation: the EORP-AF General Long-Term Registry. Europace, 2019, 21, 1013-1022.	1.7	47
135	When Should Cardiologists Suspect Anderson-Fabry Disease?. American Journal of Cardiology, 2010, 106, 1492-1499.	1.6	46
136	Prevalence and Prognostic Impact of Chronic Obstructive Pulmonary Disease in Patients with Chronic Heart Failure: Data from the GISSI-HF Trial. Cardiology, 2017, 136, 128-137.	1.4	46
137	Efficacy and Safety of Ivabradine in Patients With Severe Chronic Systolic Heart Failure (from the) Tj ETQq1 1 0.784314 rgBT /Overlock 45	1.6	45
138	Oxidative Stress Biomarkers and Incidence of Postoperative Atrial Fibrillation in the Omega-3 Fatty Acids for Prevention of Postoperative Atrial Fibrillation (OPERA) Trial. Journal of the American Heart Association, 2015, 4, .	3.7	43
139	Wine consumption and risk of cardiovascular events after myocardial infarction: Results from the GISSI-Prevenzione trial. International Journal of Cardiology, 2013, 163, 282-287.	1.7	42
140	Risk following hospitalization in stable chronic systolic heart failure. European Journal of Heart Failure, 2013, 15, 885-891.	7.1	42
141	The effect of heart rate reduction with ivabradine on renal function in patients with chronic heart failure: an analysis from <scp>SHIFT</scp>. European Journal of Heart Failure, 2014, 16, 426-434.	7.1	42
142	Regional differences in presentation and treatment of patients with atrial fibrillation in Europe: a report from the EURObservational Research Programme Atrial Fibrillation (EORP-AF) Pilot General Registry. Europace, 2015, 17, 194-206.	1.7	41
143	Duration of chronic heart failure affects outcomes with preserved effects of heart rate reduction with ivabradine: findings from SHIFT. European Journal of Heart Failure, 2018, 20, 373-381.	7.1	41
144	Do statins reduce the risk of myocardial infarction in patients with heart failure? A pooled individual-level reanalysis of CORONA and GISSI-HF. European Journal of Heart Failure, 2015, 17, 434-441.	7.1	39

#	ARTICLE	IF	CITATIONS
145	Chronic exposure to ivabradine reduces readmissions in the vulnerable phase after hospitalization for worsening systolic heart failure: a post-hoc analysis of <sc>SHIFT</sc>. European Journal of Heart Failure, 2016, 18, 1182-1189.	7.1	39
146	Rationale and design of the CONFIRM-HF study: a double-blind, randomized, placebo-controlled study to assess the effects of intravenous ferric carboxymaltose on functional capacity in patients with chronic heart failure and iron deficiency. ESC Heart Failure, 2014, 1, 52-58.	3.1	38
147	Top ten risk factors for morbidity and mortality in patients with chronic systolic heart failure and elevated heart rate: The SHIFT Risk Model. International Journal of Cardiology, 2015, 184, 163-169.	1.7	38
148	Fish Oil and Perioperative Bleeding. Circulation: Cardiovascular Quality and Outcomes, 2018, 11, e004584.	2.2	36
149	Factors associated with postoperative atrial fibrillation and other adverse events after cardiac surgery. Journal of Thoracic and Cardiovascular Surgery, 2018, 155, 242-251.e10.	0.8	34
150	Prognostic impact of in-hospital hyperglycemia in hospitalized patients with acute heart failure: Results of the IN-HF (Italian Network on Heart Failure) Outcome registry. International Journal of Cardiology, 2016, 203, 587-593.	1.7	33
151	In-hospital and 12-month follow-up outcome from the ESC-EORP EHRA Atrial Fibrillation Ablation Long-Term registry: sex differences. Europace, 2020, 22, 66-73.	1.7	33
152	The 30-day metric in acute heart failure revisited: data from <sc>IN-HF</sc> Outcome, an Italian nationwide cardiology registry. European Journal of Heart Failure, 2015, 17, 1032-1041.	7.1	32
153	Self-reported physical activity and major adverse events in patients with atrial fibrillation: a report from the EURObservational Research Programme Pilot Survey on Atrial Fibrillation (EORP-AF) General Registry. Europace, 2017, 19, euw150.	1.7	32
154	High-sensitivity troponin T, NT-proBNP and glomerular filtration rate: A multimarker strategy for risk stratification in chronic heart failure. International Journal of Cardiology, 2019, 277, 166-172.	1.7	32
155	The Ï-3 fatty acids for Prevention of Post-Operative Atrial Fibrillation trial rationale and design. American Heart Journal, 2011, 162, 56-63.e3.	2.7	31
156	Red blood cell oleic acid levels reflect olive oil intake while omega-3 levels reflect fish intake and the use of omega-3 acid ethyl esters: The Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico Heart Failure trial. Nutrition Research, 2016, 36, 989-994.	2.9	30
157	Frequent coexistence of chronic heart failure and chronic obstructive pulmonary disease in respiratory and cardiac outpatients: Evidence from SUSPIRIUM, a multicentre Italian survey. European Journal of Preventive Cardiology, 2017, 24, 567-576.	1.8	30
158	Prognostic impact of elevated serum uric acid levels on long-term outcomes in patients with chronic heart failure: A post-hoc analysis of the GISSI-HF (Gruppo Italiano per lo Studio della Sopravvivenza) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5 205-215.	3.4	30
159	Changes to oral anticoagulant therapy and risk of death over a 3-year follow-up of a contemporary cohort of European patients with atrial fibrillation final report of the EURObservational Research Programme on Atrial Fibrillation (EORP-AF) pilot general registry. International Journal of Cardiology, 2018, 271, 68-74.	1.7	30
160	EURObservational Research Programme: the Chronic Ischaemic Cardiovascular Disease Registry: Pilot phase (CICD-PILOT). European Heart Journal, 2016, 37, 152-160.	2.2	29
161	Randomized evaluation of intralesion versus intracoronary abciximab and aspiration thrombectomy in patients with ST-elevation myocardial infarction: The COCTAIL II trial. American Heart Journal, 2015, 170, 1116-1123.	2.7	27
162	Regular Wine Consumption in Chronic Heart Failure. Circulation: Heart Failure, 2015, 8, 428-437.	3.9	26

#	ARTICLE	IF	CITATIONS
163	Distinct gene expression profiles associated with Notch ligands Delta-like 4 and Jagged1 in plaque material from peripheral artery disease patients: a pilot study. <i>Journal of Translational Medicine</i> , 2017, 15, 98.	4.4	26
164	Progression of Renal Impairment and Chronic Kidney Disease in Chronic Heart Failure: An Analysis From GISSI-HF. <i>Journal of Cardiac Failure</i> , 2017, 23, 2-9.	1.7	26
165	Effect of Combining Ivabradine and β -Blockers: Focus on the Use of Carvedilol in the SHIFT Population. <i>Cardiology</i> , 2015, 131, 218-224.	1.4	25
166	Influence of background treatment with mineralocorticoid receptor antagonists on ivabradine's effects in patients with chronic heart failure. <i>European Journal of Heart Failure</i> , 2013, 15, 79-84.	7.1	24
167	Repeated Heart Rate Measurement and Cardiovascular Outcomes in Left Ventricular Systolic Dysfunction. <i>American Journal of Medicine</i> , 2015, 128, 1102-1108.e6.	1.5	24
168	Treatment with inotropes and related prognosis in acute heart failure: Contemporary data from the Italian Network on Heart Failure (IN-HF) Outcome registry. <i>Journal of Heart and Lung Transplantation</i> , 2014, 33, 1056-1065.	0.6	23
169	Overweight and obesity in patients with atrial fibrillation: Sex differences in 1-year outcomes in the EORP-AF General Pilot Registry. <i>Journal of Cardiovascular Electrophysiology</i> , 2018, 29, 566-572.	1.7	23
170	Differences between familial and sporadic dilated cardiomyopathy: ESC EORP Cardiomyopathy & Myocarditis registry. <i>ESC Heart Failure</i> , 2021, 8, 95-105.	3.1	23
171	Impact of left bundle branch block on heart rate and its relationship to treatment with ivabradine in chronic heart failure. <i>European Journal of Heart Failure</i> , 2013, 15, 1044-1052.	7.1	22
172	Non-adherence to ivabradine and placebo and outcomes in chronic heart failure: an analysis from SHIFT. <i>European Journal of Heart Failure</i> , 2016, 18, 672-683.	7.1	21
173	Percutaneous coronary intervention reduces mortality in myocardial infarction patients with comorbidities: Implications for elderly patients with diabetes or kidney disease. <i>International Journal of Cardiology</i> , 2017, 249, 83-89.	1.7	21
174	Relationship between physical activity and long-term outcomes in patients with stable coronary artery disease. <i>European Journal of Preventive Cardiology</i> , 2020, 27, 426-436.	1.8	21
175	Serial optical coherence tomography imaging of ACS-causing culprit plaques. <i>EuroIntervention</i> , 2015, 11, 319-324.	3.2	21
176	Clinical features, and in-hospital and 1-year mortalities of patients with acute heart failure and severe renal dysfunction. Data from the Italian Registry IN-HF Outcome. <i>International Journal of Cardiology</i> , 2013, 168, 3691-3697.	1.7	20
177	Effect of Visit-to-Visit Variation of Heart Rate and Systolic Blood Pressure on Outcomes in Chronic Systolic Heart Failure: Results From the Systolic Heart Failure Treatment With the β -Blocker Inhibitor Ivabradine Trial (SHIFT) Trial. <i>Journal of the American Heart Association</i> , 2016, 5, e008881.	3.7	20
178	The battle against COVID-19: mortality in Italy. <i>European Heart Journal</i> , 2020, 41, 2050-2052.	2.2	20
179	Patient factors associated with titration of medical therapy in patients with heart failure with reduced ejection fraction: data from the QUALIFY international registry. <i>ESC Heart Failure</i> , 2021, 8, 861-871.	3.1	20
180	Rationale and Design of a Prospective Trial to Assess the Sensitivity and Positive Predictive Value of Implantable Intrathoracic Impedance Monitoring in the Prediction of Heart Failure Hospitalizations: The SENSE-HF Study. <i>Journal of Cardiac Failure</i> , 2009, 15, 394-400.	1.7	19

#	ARTICLE	IF	CITATIONS
181	Independent academic Data Monitoring Committees for clinical trials in cardiovascular and cardiometabolic diseases. <i>European Journal of Heart Failure</i> , 2017, 19, 449-456.	7.1	19
182	ESC EORP Cardiomyopathy Registry: real-life practice of genetic counselling and testing in adult cardiomyopathy patients. <i>ESC Heart Failure</i> , 2020, 7, 3013-3021.	3.1	19
183	Evolution of renal function during and after an episode of cardiac decompensation: results from the Italian survey on acute heart failure. <i>Journal of Cardiovascular Medicine</i> , 2010, 11, 234-243.	1.5	18
184	Prognostic impact of metabolic syndrome in patients with chronic heart failure: Data from GISSI-HF trial. <i>International Journal of Cardiology</i> , 2015, 178, 85-90.	1.7	18
185	Has the "epidemic" of heart failure been replaced by a tsunami of comorbidities?. <i>European Journal of Heart Failure</i> , 2016, 18, 500-502.	7.1	18
186	Acute heart failure: lessons learned, roads ahead. <i>European Journal of Heart Failure</i> , 2018, 20, 842-850.	7.1	17
187	Cardiac Prevention and Rehabilitation 3.0: From acute to chronic phase. Position Paper of the Italian Association for Cardiovascular Prevention and Rehabilitation (GICR-IACPR). <i>Monaldi Archives for Chest Disease</i> , 2018, 88, 1004.	0.6	17
188	Do we need clinical registries?. <i>European Heart Journal</i> , 2014, 35, 7-9.	2.2	16
189	Beta-blockers can improve survival in medically-treated patients with severe symptomatic aortic stenosis. <i>International Journal of Cardiology</i> , 2015, 190, 15-17.	1.7	16
190	Improving the appropriateness of sudden arrhythmic death primary prevention by implantable cardioverter-defibrillator therapy in patients with low left ventricular ejection fraction. Point of view. <i>Journal of Cardiovascular Medicine</i> , 2016, 17, 245-255.	1.5	16
191	Prognostic effects of rosuvastatin in patients with co-existing chronic obstructive pulmonary disease and chronic heart failure: A sub-analysis of GISSI-HF trial. <i>Pulmonary Pharmacology and Therapeutics</i> , 2017, 44, 16-23.	2.6	16
192	Lower extremities peripheral arterial disease among patients admitted to cardiac rehabilitation: The THINKPAD registry. <i>International Journal of Cardiology</i> , 2014, 171, 192-198.	1.7	15
193	Efficacy Profile of Ivabradine in Patients with Heart Failure plus Angina Pectoris. <i>Cardiology</i> , 2017, 136, 138-144.	1.4	15
194	Adiponectin in chronic heart failure: influence of diabetes and genetic variants. <i>European Journal of Clinical Investigation</i> , 2011, 41, 1330-1338.	3.4	14
195	Should we revise our approach to 'optimal medical therapy'? The case of chronic heart failure. <i>European Heart Journal</i> , 2013, 34, 2792-2794.	2.2	14
196	Pregnancy Outcomes in Women After Arterial Switch Operation for Transposition of the Great Arteries: Results From ROPAC (Registry of Pregnancy and Cardiac Disease) of the European Society of Cardiology EURObservational Research Programme. <i>Journal of the American Heart Association</i> , 2021, 10, e018176.	3.7	14
197	Regional differences in referral, procedures, and outcome after ablation for atrial fibrillation in Europe: a report from the Atrial Fibrillation Ablation Pilot Registry of the European Society of Cardiology. <i>Europace</i> , 2016, 18, 191-200.	1.7	13
198	A low plasma 1,25(OH) 2 vitamin D/PTH (1⁸⁴) ratio predicts worsening of renal function in patients with chronic heart failure. <i>International Journal of Cardiology</i> , 2016, 224, 220-225.	1.7	12

#	ARTICLE	IF	CITATIONS
199	The chronic ischaemic cardiovascular disease ESC Pilot Registry: Results of the six-month follow-up. <i>European Journal of Preventive Cardiology</i> , 2018, 25, 377-387.	1.8	12
200	Relation between plasma ceramides and cardiovascular death in chronic heart failure: A subset analysis of the GISSI-HF trial. <i>ESC Heart Failure</i> , 2020, 7, 3288-3297.	3.1	12
201	Randomized trial of standard versus ClearWay-infused abciximab and thrombectomy in myocardial infarction. <i>Journal of Cardiovascular Medicine</i> , 2013, 14, 364-371.	1.5	12
202	Appropriateness of Prescriptions of Recommended Treatments in Organisation for Economic Co-operation and Development Health Systems: Findings Based on the Long-Term Registry of the European Society of Cardiology on Heart Failure. <i>Value in Health</i> , 2015, 18, 1098-1104.	0.3	11
203	Beneficial effects of ivabradine in patients with heart failure, low ejection fraction, and heart rate above 77 b.p.m.. <i>ESC Heart Failure</i> , 2019, 6, 1199-1207.	3.1	11
204	Impact of monitoring on detection of arrhythmia recurrences in the ESC-EHRA EORP atrial fibrillation ablation long-term registry. <i>Europace</i> , 2019, 21, 1802-1808.	1.7	11
205	Atrial fibrillation, anticoagulation management and risk of stroke in the Cardiomyopathy/Myocarditis registry of the EURObservational Research Programme of the European Society of Cardiology. <i>ESC Heart Failure</i> , 2020, 7, 3601-3609.	3.1	11
206	Profile and treatment of chronic coronary syndromes in European Society of Cardiology member countries: The ESC EORP CICD-LT registry. <i>European Journal of Preventive Cardiology</i> , 2021, 28, 432-445.	1.8	11
207	Clinical and prognostic value of spot urinary creatinine in chronic heart failure – An analysis from GISSI-HF. <i>American Heart Journal</i> , 2017, 188, 189-195.	2.7	10
208	Influence of socioeconomic factors on pregnancy outcome in women with structural heart disease. <i>Heart</i> , 2018, 104, 745-752.	2.9	10
209	Current use of cardiac magnetic resonance in tertiary referral centres for the diagnosis of cardiomyopathy: the ESC EORP Cardiomyopathy/Myocarditis Registry. <i>European Heart Journal Cardiovascular Imaging</i> , 2021, 22, 781-789.	1.2	10
210	Pacemaker need after sutureless aortic valve replacement: the role of the learning curve. <i>Journal of Cardiovascular Medicine</i> , 2021, 22, 133-138.	1.5	9
211	Cancer in chronic heart failure patients in the GISSI-HF trial. <i>European Journal of Clinical Investigation</i> , 2020, 50, e13273.	3.4	8
212	Modes of death and prognostic outliers in chronic heart failure. <i>American Heart Journal</i> , 2019, 208, 100-109.	2.7	7
213	Which patients with atrial fibrillation undergo an ablation procedure today in Europe? A report from the ESC-EHRA-EORP Atrial Fibrillation Ablation Long-Term and Atrial Fibrillation General Pilot Registries. <i>Europace</i> , 2020, 22, 250-258.	1.7	7
214	Priorities for Cath labs in the COVID-19 tsunami. <i>European Heart Journal</i> , 2020, 41, 1784-1785.	2.2	7
215	“Observational medicine™: registries and Electronic Health Recording for science and health systems governance. <i>European Journal of Heart Failure</i> , 2016, 18, 1093-1095.	7.1	6
216	Prospective Evaluation of Clinico-Pathological Predictors of Postoperative Atrial Fibrillation. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2020, 13, e008382.	4.8	6

#	ARTICLE	IF	CITATIONS
217	Impact of centre volume on atrial fibrillation ablation outcomes in Europe: a report from the ESC EHRA EORP Atrial Fibrillation Ablation Long-Term (AFA LT) Registry. <i>Europace</i> , 2021, 23, 49-58.	1.7	6
218	Impact of malignancy on outcomes in European patients with atrial fibrillation: A report from the ESC-EHRA EURObservational research programme in atrial fibrillation general long-term registry. <i>European Journal of Clinical Investigation</i> , 2022, 52, e13773.	3.4	6
219	CardioPulse Articles. <i>European Heart Journal</i> , 2011, 32, 1173-1181.	2.2	5
220	Prevalence of risk of thrombosis and of bleeding and antithrombotic treatment in patients with heart failure. <i>European Journal of Heart Failure</i> , 2020, 22, 906-910.	7.1	5
221	Testing longitudinal data for prognostication in ambulatory heart failure patients with reduced ejection fraction. A proof of principle from the GISSI-HF database. <i>International Journal of Cardiology</i> , 2020, 313, 89-96.	1.7	5
222	Coffee, Atrial Fibrillation, and Circulating Ceramides in Patients with Chronic Heart Failure. <i>Journal of Agricultural and Food Chemistry</i> , 2021, 69, 11236-11245.	5.2	5
223	Cardiac troponins and adverse outcomes in European patients with atrial fibrillation: A report from the ESC-EHRA EORP atrial fibrillation general long-term registry. <i>European Journal of Internal Medicine</i> , 2022, 99, 45-56.	2.2	5
224	The Anp genetic variant Rs5068 and circulating levels of natriuretic peptides in patients with chronic heart failure. <i>International Journal of Cardiology</i> , 2014, 176, 1249-1251.	1.7	4
225	Italian survey on prevalence and disease management of chronic heart failure and chronic obstructive pulmonary disease comorbidity in ambulatory patients. SUSPIRIUM study rationale and design. <i>Monaldi Archives for Chest Disease</i> , 2015, 82, 29-34.	0.6	4
226	Update on ivabradine for heart failure. <i>Trends in Cardiovascular Medicine</i> , 2016, 26, 444-449.	4.9	4
227	The evolution of cardiology: changes, future challenges and opportunities. <i>Future Cardiology</i> , 2017, 13, 161-171.	1.2	4
228	Observational research as a platform for evidence-based public health policies and learning health systems. <i>European Heart Journal</i> , 2017, 38, 1891-1894.	2.2	4
229	A brief overview of cardiac resynchronization therapy and its current use in clinical practice. <i>European Journal of Heart Failure</i> , 2017, 19, 1280-1283.	7.1	4
230	Big data: is clinical practice changing?. <i>European Heart Journal Supplements</i> , 2019, 21, B98-B102.	0.1	4
231	Key words to be adopted for COVID-19 research. <i>European Heart Journal</i> , 2020, 41, 4229-4230.	2.2	4
232	Cardiac Calcifications: Phenotypes, Mechanisms, Clinical and Prognostic Implications. <i>Biology</i> , 2022, 11, 414.	2.8	4
233	Reply. <i>Journal of the American College of Cardiology</i> , 2014, 63, 2584-2586.	2.8	3
234	Effect of Ivabradine on Early Readmissions After Hospitalization for Worsening Heart Failure. <i>JACC: Heart Failure</i> , 2015, 3, 268-269.	4.1	3

#	ARTICLE	IF	CITATIONS
235	It's time to move on from counting co-morbidities to curing them: the case of chronic heart failure—chronic obstructive pulmonary disease co-morbidity. <i>European Journal of Heart Failure</i> , 2018, 20, 193-196.	7.1	3
236	Awareness and appropriateness of the management of preclinical heart failure in outpatient clinics in Italy: Insights from the VASTISSIMO study - Evaluation of the Appropriateness of The preclinical phase (Stage A and Stage B) of Heart Failure Management in Outpatient Clinics in Italy. <i>Monaldi Archives for Chest Disease</i> , 2019, 89, .	0.6	3
237	Clinical characteristics of heart failure patients undergoing atrial fibrillation ablation today in Europe. Data from the atrial fibrillation registries of the European Society of Cardiology and the European Heart Rhythm Association. <i>European Journal of Heart Failure</i> , 2019, 21, 690-693.	7.1	3
238	The “Black Death”™ and the physician at the time of COVID-19. <i>European Heart Journal</i> , 2020, 41, 3501-3502.	2.2	3
239	Prospective follow-up in various subtypes of cardiomyopathies: insights from the ESC EORP Cardiomyopathy Registry. <i>European Heart Journal Quality of Care & Clinical Outcomes</i> , 2021, 7, 134-142.	4.0	3
240	Impact of anthropometric factors on outcomes in atrial fibrillation patients: analysis on 10%220 patients from the European Society of Cardiology (ESC)-European Heart Rhythm Association (EHRA) EurObservational Research Programme on Atrial Fibrillation (EORP-AF) general long-term registry. <i>European Journal of Preventive Cardiology</i> , 0, , .	1.8	3
241	MOGE(S) nosology in low-to-middle-income countries. <i>Nature Reviews Cardiology</i> , 2014, 11, 307-307.	13.7	2
242	Predictors of mortality in acute heart failure and severe renal dysfunction. Does formula for glomerular filtration rate have any impact? Data from IN-HF outcome registry. <i>International Journal of Cardiology</i> , 2014, 172, e96-e97.	1.7	2
243	The Endless Story of Digitalis. <i>American Journal of Medicine</i> , 2014, 127, e11.	1.5	2
244	Response to Letter Regarding Article, “Risk of Stroke in Chronic Heart Failure Patients Without Atrial Fibrillation: Analysis of the Controlled Rosuvastatin in Multinational Trial Heart Failure (CORONA) and the Gruppo Italiano per lo Studio della Sopravvivenza nell’Insufficienza Cardiaca-Heart Failure (GISSI-HF) Trials.” <i>Circulation</i> , 2015, 132, e358.	1.6	2
245	Budget Impact of Adding Ivabradine to Standard of Care in Patients with Chronic Systolic Heart Failure in the United States. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2016, 22, 1064-1071.	0.9	2
246	Use and Disuse of Observational Research: The Case of Remote Monitoring in Heart Failure. <i>Cardiology</i> , 2017, 137, 14-19.	1.4	2
247	Financial impact of ivabradine on reducing heart failure penalties under the Hospital Readmission Reduction Program. <i>Current Medical Research and Opinion</i> , 2017, 33, 185-191.	1.9	2
248	Brachial pulse pressure in acute heart failure. Results of the Heart Failure Registry. <i>ESC Heart Failure</i> , 2019, 6, 1167-1177.	3.1	2
249	The ESC-EORP Chronic Ischaemic Cardiovascular Disease Long Term (CICD LT) registry. <i>European Heart Journal Quality of Care & Clinical Outcomes</i> , 2021, 7, 28-33.	4.0	2
250	Patient, hospital and country-level risk factors of all-cause mortality among patients with chronic heart failure: Prospective international cohort study. <i>PLoS ONE</i> , 2021, 16, e0250931.	2.5	2
251	One year on: The impact of COVID-19 on clinical research. <i>European Journal of Internal Medicine</i> , 2021, 92, 24-27.	2.2	2
252	Atrial fibrillation ablation in heart failure: Findings from the ESC-EHRA EORP Atrial Fibrillation Ablation long-term (AFA LT) registry. <i>International Journal of Cardiology</i> , 2022, 346, 19-26.	1.7	2

#	ARTICLE	IF	CITATIONS
253	Heart failure and catheter ablation of atrial fibrillation: Navigating the difficult waters of heart failure phenotypes. <i>European Journal of Internal Medicine</i> , 2022, 99, 13-18.	2.2	2
254	Clinical trials: conventional or pragmatic?. <i>European Journal of Heart Failure</i> , 2022, 24, 596-599.	7.1	2
255	Regression of severe bare metal stent restenosis: IVUS and OCT findings. <i>International Journal of Cardiology</i> , 2015, 185, 78-80.	1.7	1
256	Evaluation of the appropriateness of the preclinical phase (stage A and stage B) of heart failure Management in Outpatient clinics in Italy rationale and design of the "VASTISSIMO" study. <i>Journal of Cardiovascular Medicine</i> , 2016, 17, 501-509.	1.5	1
257	Biophysical signalling from and to the (stem) cells: a novel path to regenerative medicine. <i>European Journal of Heart Failure</i> , 2016, 18, 1405-1407.	7.1	1
258	Reply. <i>JACC: Heart Failure</i> , 2018, 6, 810-811.	4.1	1
259	Adenosine usage during AF ablation in Europe and selected long-term findings from the ESC-EHRA EORP Atrial Fibrillation Ablation Long-Term registry. <i>Journal of Interventional Cardiac Electrophysiology</i> , 2021, 60, 395-406.	1.3	1
260	CARDIAC chronotropic effects of sleep-disordered breathing in patients with heart failure. <i>Journal of Sleep Research</i> , 2021, 30, e13160.	3.2	1
261	Response to Letter Regarding Article, "Wolff-Parkinson-White Syndrome in the Era of Catheter Ablation: Insights From a Registry Study of 2169 Patients", <i>Circulation</i> , 2015, 131, e499.	1.6	0
262	Comments on meta-analysis of ivabradine as adjuvant treatment for chronic heart failure by Mizzaci et al.. <i>International Journal of Cardiology</i> , 2017, 239, 2.	1.7	0
263	Cardiac resynchronization therapy in clinical practice: some interesting news but methodological advances are needed. <i>European Journal of Heart Failure</i> , 2018, 20, 1052-1054.	7.1	0
264	Potential advantages and drawbacks of new methodologies for the conduction of observational research. <i>European Heart Journal Supplements</i> , 2018, 20, C11-C13.	0.1	0
265	Scientific progress and clinical uncertainty. <i>European Heart Journal Supplements</i> , 2020, 22, L146-L150.	0.1	0
266	Pregnancy Outcomes in Women With Cardiovascular Disease: Evolving Trends Over 10 Years in the ESC Registry of Pregnancy and Cardiac Disease (ROPAC). <i>Obstetrical and Gynecological Survey</i> , 2020, 75, 279-280.	0.4	0